Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the safety, tolerability and treatment effect of the
orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild
to moderate COVID-19 and to generate proof of concept for future trials.